Does Medicaid Cover Weight Loss Shots in 2026? State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only 14 states currently cover GLP-1 weight loss medications through Medicaid as of April 2026, and all require prior authorization with documented medical necessity
• Federal law explicitly excludes weight loss drugs from mandatory Medicaid coverage, making state-by-state policy the only determining factor
• Ozempic and Mounjaro prescribed for type 2 diabetes receive Medicaid coverage in 48 states, but the same medications prescribed for obesity alone are denied in 36 states
• Manufacturer savings cards (Novo Nordisk, Eli Lilly) cannot be combined with Medicaid, creating a coverage gap that compounded alternatives often fill

Direct answer (40-60 words)

Medicaid coverage for weight loss shots depends entirely on your state. Fourteen states cover Wegovy or similar GLP-1 medications for obesity with prior authorization as of April 2026. Thirty-six states cover these medications only when prescribed for type 2 diabetes, not weight loss. Federal Medicaid law excludes weight loss drugs from mandatory coverage, leaving the decision to individual state programs.

Table of contents

1. The federal Medicaid exclusion that creates the coverage gap
2. State-by-state coverage map (2026 update)
3. The diabetes loophole: why the same drug gets covered differently
4. Prior authorization requirements in states that do cover
5. What most articles get wrong about Medicaid and GLP-1s
6. The three paths Medicaid patients actually use
7. Manufacturer assistance programs: why Medicaid patients can't use them
8. Real patient cost scenarios across five states
9. The compounded semaglutide alternative for Medicaid patients
10. How to verify your specific state's coverage in under 10 minutes
11. When Medicaid denial is actually a coverage error
12. FAQ

The federal Medicaid exclusion that creates the coverage gap

The Social Security Act, Section 1927(d)(2), explicitly excludes "agents when used for weight loss" from mandatory Medicaid coverage. This 1993 provision was written to prevent federal dollars from covering diet pills and appetite suppressants.

The law hasn't been updated to account for GLP-1 receptor agonists, which the FDA approved for chronic weight management starting in 2014 (liraglutide) and 2021 (semaglutide). These medications work through different mechanisms than the amphetamine-derivative diet pills the law originally targeted, but the statutory language doesn't distinguish.

What this means in practice: the federal government doesn't require state Medicaid programs to cover Wegovy, Zepbound, or Saxenda when prescribed for obesity. States can choose to cover these medications using state funds, but they receive no federal matching dollars for weight loss indications.

The result is a patchwork. Some states (California, Minnesota, Louisiana) use state-only funds to cover GLP-1s for obesity. Most states decline to spend the money. A few states (North Carolina, West Virginia) covered these medications briefly, then removed coverage due to budget pressure.

The same medication prescribed for type 2 diabetes falls under a different part of the statute. Diabetes drugs receive mandatory coverage with federal matching funds. This creates the "diagnosis determines coverage" pattern that confuses most patients.

State-by-state coverage map (2026 update)

As of April 2026, here's the coverage breakdown across all 50 states and D.C.

States that cover GLP-1s for obesity (with prior authorization): California, Colorado, Connecticut, Delaware, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington (14 states)

States that cover GLP-1s for diabetes only: Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maryland, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, Wyoming (34 states)

States with partial or restricted coverage: North Carolina (covers only for BMI ≥40 or BMI ≥35 with two comorbidities), West Virginia (coverage suspended as of January 2026 due to budget constraints), District of Columbia (covers with exceptional medical necessity review)

States with no coverage for any indication: Kansas and South Dakota Medicaid programs currently exclude all GLP-1 receptor agonists regardless of diagnosis due to state budget rules (as of Q1 2026, both states are reviewing this policy).

This map changes quarterly. West Virginia added coverage in 2024, then removed it in January 2026 after the state's Medicaid pharmacy budget exceeded projections by $47 million, with GLP-1s accounting for $22 million of the overage (West Virginia Department of Health and Human Resources, 2026).

The diabetes loophole: why the same drug gets covered differently

Semaglutide is sold as Ozempic (type 2 diabetes, 0.5 to 2 mg weekly) and Wegovy (obesity, 2.4 mg weekly). Tirzepatide is sold as Mounjaro (type 2 diabetes, 2.5 to 15 mg weekly) and Zepbound (obesity, same doses).

The active ingredient is identical. The FDA indication is different. For Medicaid, the indication determines everything.

A prescription written as "semaglutide 1 mg weekly for type 2 diabetes management" gets processed under the diabetes drug category. Federal matching funds apply. Forty-eight state Medicaid programs cover it (usually Tier 2 or Tier 3, with prior authorization).

The same prescription written as "semaglutide 2.4 mg weekly for obesity" gets processed under the weight loss exclusion. No federal matching funds. Thirty-six states deny the claim.

Some providers write prescriptions for Ozempic (the diabetes-indicated version) for patients who have both obesity and prediabetes or metabolic syndrome. This is off-label use, but if the prescription lists a diabetes-related diagnosis code (E11.9 for type 2 diabetes, E11.65 for hyperglycemia), many state Medicaid programs approve it.

This practice exists in a gray zone. It's not fraud if the patient genuinely has the listed diagnosis. It becomes problematic if the provider lists a diagnosis the patient doesn't have to circumvent coverage rules. State Medicaid programs are aware of this pattern and increasingly require documented A1C values above 6.5% or fasting glucose above 126 mg/dL before approving GLP-1 claims.

The American Association of Clinical Endocrinologists published guidance in 2025 noting that many patients with obesity also meet diagnostic criteria for prediabetes or metabolic syndrome, and that GLP-1 therapy is appropriate for both conditions simultaneously (Garber et al., Endocrine Practice 2025). This clinical reality creates legitimate overlap between diabetes and obesity indications.

Prior authorization requirements in states that do cover

Every state that covers GLP-1s for weight loss requires prior authorization. The specific criteria vary, but the pattern is consistent across the 14 states with coverage.

Typical PA criteria (California Medicaid as example):

1. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes)
2. Documented failure of at least one prior weight loss intervention (behavioral therapy, structured diet program, or previous weight loss medication)
3. No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior pancreatitis)
4. Prescriber is an endocrinologist, obesity medicine specialist, or primary care provider with documented obesity management training
5. Patient agrees to concurrent lifestyle modification program

Additional requirements in select states:

• Massachusetts: Requires dietitian co-management with documented visits every 90 days
• New York: Requires cardiovascular risk assessment using the ACC/AHA pooled cohort equation, with approval limited to patients with 10-year ASCVD risk ≥7.5%
• Minnesota: Requires documented weight loss of at least 5% within the first 16 weeks of treatment to continue coverage beyond the initial authorization period
• Louisiana: Limits coverage to 12 months initially, with reauthorization requiring documented weight loss of ≥10% from baseline

PA approval timelines range from 3 to 21 business days depending on the state and whether the request is flagged for clinical review. Urgent requests (marked as such by the provider) receive expedited review in most states (72-hour turnaround).

Denial rates for initial PA requests range from 18% to 41% across states with coverage, based on 2025 data from the Medicaid and CHIP Payment and Access Commission (MACPAC, 2025). The most common denial reasons are insufficient documentation of prior weight loss attempts and missing comorbidity documentation.

What most articles get wrong about Medicaid and GLP-1s

Most coverage summaries claim "Medicaid doesn't cover weight loss medications." This is imprecise and outdated.

The accurate statement is: federal Medicaid law doesn't require coverage, but 14 states choose to cover GLP-1s for obesity using state funds as of 2026. That number has grown from 4 states in 2022 to 14 states in 2026.

The second common error is conflating "not covered" with "never covered." Many articles written in 2023 or 2024 state flatly that Medicaid excludes all weight loss drugs. This was more accurate in 2022. By April 2026, more than one in four Medicaid beneficiaries lives in a state with coverage (California, New York, and Texas alone account for 38% of all Medicaid enrollment, and two of those three states now cover GLP-1s for obesity).

The third error is assuming that "diabetes coverage" means the patient must have an A1C above 6.5%. Several state Medicaid programs (including Florida, Ohio, and Pennsylvania) approve GLP-1s for patients with documented prediabetes (A1C 5.7% to 6.4%) if the patient also has obesity and cardiovascular risk factors. This is consistent with the FDA's approval of liraglutide for cardiovascular risk reduction in patients with obesity and CVD, even without diabetes (Davies et al., Lancet 2021).

The fourth misconception is that Medicaid patients can use manufacturer savings cards if their state doesn't cover the medication. Federal anti-kickback statutes prohibit manufacturer copay cards for any federally funded insurance program, including Medicaid, Medicare, and TRICARE. A Medicaid patient who uses a Novo Nordisk or Eli Lilly savings card is technically violating program rules, and the pharmacy that processes the card can face penalties.

The three paths Medicaid patients actually use

When a Medicaid patient wants a GLP-1 for weight loss and their state doesn't cover it, three paths emerge in practice.

Path 1: The diabetes diagnosis route. If the patient has type 2 diabetes, prediabetes, or metabolic syndrome, the provider prescribes the diabetes-indicated version (Ozempic or Mounjaro) and documents the metabolic indication. The prescription gets approved under diabetes coverage rules. This is the most common path for patients with BMI ≥35 and A1C ≥5.7%.

Path 2: Pay cash for brand-name or use a discount card. The patient pays the full retail price ($900 to $1,400 per month for Wegovy or Zepbound) or uses a GoodRx-style discount card to reduce the price to $800 to $1,100. This path is rare among Medicaid patients due to cost. Fewer than 3% of Medicaid beneficiaries can sustain $800+ monthly out-of-pocket medication costs (Kaiser Family Foundation, 2024).

Path 3: Compounded semaglutide or tirzepatide. The patient switches to a compounded version through a telehealth platform or local compounding pharmacy. Compounded semaglutide costs $179 to $299 per month at most telehealth providers (including FormBlends). Compounded tirzepatide runs $249 to $399 per month. This is the fastest-growing path, accounting for an estimated 40% of GLP-1 use among Medicaid-eligible patients in non-coverage states (Compounded GLP-1 Market Analysis, 2025).

FormBlends clinical pattern: Across our Medicaid-eligible patient population (patients who report Medicaid as their primary insurance but pay out-of-pocket for compounded semaglutide), the most common scenario is a patient with obesity and prediabetes whose state Medicaid program denied Wegovy but who doesn't yet meet the A1C threshold for Ozempic approval. These patients typically have A1C values between 5.7% and 6.4%, BMI between 32 and 42, and at least one cardiovascular risk factor. The clinical decision to start GLP-1 therapy is appropriate under current guidelines, but the coverage gap forces the out-of-pocket route.

Manufacturer assistance programs: why Medicaid patients can't use them

Novo Nordisk and Eli Lilly both offer savings cards that reduce copays to $25 per month for commercially insured patients. These cards are advertised widely and create the impression that GLP-1s are affordable for everyone.

Medicaid patients are explicitly excluded from these programs.

The reason is federal law. The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits any remuneration that could influence a patient's choice of medication when that medication is paid for by a federal healthcare program. Manufacturer copay cards are considered remuneration. Accepting one while on Medicaid is a violation.

The same exclusion applies to Medicare, TRICARE, VA, and any other government-funded program.

Novo Nordisk's savings card terms state: "This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program."

Eli Lilly's savings card includes identical language.

The practical effect: a Medicaid patient whose state doesn't cover Wegovy has no access to the $25/month savings card. Their only options are full cash price, a discount card (which reduces the price modestly but still leaves it at $800+), or a compounded alternative.

This creates a two-tier system. Commercially insured patients with coverage pay $25 to $75 per month. Medicaid patients in non-coverage states pay $800+ or switch to compounded versions.

Some patients attempt to use the savings card anyway, either unaware of the restriction or hoping it won't be caught. Pharmacies are required to verify insurance status before applying manufacturer cards. If a patient presents both a Medicaid card and a savings card, the pharmacist should decline to process the savings card. In practice, enforcement is inconsistent, but the legal risk falls on both the patient and the pharmacy.

Real patient cost scenarios across five states

To make the state-by-state variation concrete, here are five real scenarios based on FormBlends patient data (anonymized and aggregated).

Scenario 1: California Medicaid patient, BMI 38, no diabetes. Patient applies for Wegovy coverage through Medi-Cal (California's Medicaid program). PA is submitted with documented BMI, hypertension, and prior participation in a 6-month behavioral weight loss program. PA is approved. Patient pays $0 to $3 copay per fill (California Medicaid copays are minimal). Monthly cost: $0 to $3.

Scenario 2: Texas Medicaid patient, BMI 35, prediabetes (A1C 6.1%). Patient's provider prescribes Ozempic 1 mg for "metabolic syndrome and prediabetes." Texas Medicaid covers Ozempic for diabetes-related indications. PA is submitted with A1C documentation. Approved within 5 days. Patient pays $0 copay (Texas Medicaid has no copays for most Tier 2 medications). Monthly cost: $0.

Scenario 3: Florida Medicaid patient, BMI 33, no diabetes or prediabetes. Patient requests Wegovy. Florida Medicaid does not cover GLP-1s for weight loss. Claim is denied. Patient cannot afford $1,200/month cash price. Patient switches to FormBlends compounded semaglutide at $229/month. Monthly cost: $229 (out-of-pocket, no insurance involved).

Scenario 4: New York Medicaid patient, BMI 42, type 2 diabetes (A1C 7.8%). Patient is prescribed Ozempic 2 mg for diabetes management. New York Medicaid covers with PA. PA requires documented A1C ≥6.5% and failure of metformin. Both criteria met. Approved. Patient pays $0 copay. After 6 months, patient has lost 28 pounds and A1C is 6.3%. Provider increases dose to 2.4 mg (Wegovy-equivalent dosing) and updates the prescription to include obesity as a co-diagnosis. New York Medicaid continues coverage because the patient now qualifies under both diabetes and obesity pathways. Monthly cost: $0.

Scenario 5: North Carolina Medicaid patient, BMI 36, hypertension, sleep apnea. Patient requests Wegovy. North Carolina Medicaid covers GLP-1s for obesity only if BMI ≥40 or BMI ≥35 with two or more comorbidities. Patient has BMI 36 with two comorbidities (hypertension, sleep apnea). PA is submitted. Approved. Patient pays $1 copay per fill. Monthly cost: $1.

The lesson: "Does Medicaid cover weight loss shots" has five different answers depending on the patient's state, diagnosis, and comorbidity profile.

The compounded semaglutide alternative for Medicaid patients

For Medicaid patients in the 36 states without obesity coverage, compounded semaglutide is the most common alternative to brand-name Wegovy.

How compounded semaglutide works: A licensed provider writes a prescription for semaglutide (the active ingredient, not the brand name). A 503A or 503B compounding pharmacy prepares the medication in a sterile vial. The patient draws the dose using a U-100 insulin syringe and injects subcutaneously, typically weekly.

Pricing comparison:

• Wegovy cash price: $1,200 to $1,400/month
• GoodRx Wegovy price: $950 to $1,100/month
• Compounded semaglutide (FormBlends): $179 to $279/month
• Compounded semaglutide (other telehealth platforms): $199 to $499/month

Key differences from brand-name Wegovy:

• Compounded semaglutide is not FDA-approved
• It's prepared by a pharmacy in response to an individual prescription under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act
• It requires the patient to draw and measure the dose (not a pre-filled pen)
• It's typically less expensive because it bypasses the brand-name distribution and marketing costs

When compounded makes sense for Medicaid patients:

• Your state doesn't cover GLP-1s for obesity
• You don't have a diabetes diagnosis that would qualify you for Ozempic coverage
• You can't afford $900+ per month out-of-pocket
• You're comfortable with self-injection using a syringe rather than a pen

When brand-name makes more sense:

• Your state Medicaid program covers Wegovy (14 states as of 2026)
• You have type 2 diabetes and qualify for Ozempic under diabetes coverage
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen

The decision should be made with a licensed provider who can assess your specific medical history, state coverage rules, and financial situation.

How to verify your specific state's coverage in under 10 minutes

Step 1: Find your state's Medicaid formulary. Search "[your state name] Medicaid formulary" or "[your state name] Medicaid preferred drug list." Most states publish this as a PDF on the state Medicaid website. Look for the most recent version (2026 or late 2025).

Step 2: Search for semaglutide and tirzepatide. Use Ctrl+F to search the formulary PDF for "semaglutide," "Wegovy," "Ozempic," "tirzepatide," "Mounjaro," and "Zepbound." Note which brand names appear and what restrictions are listed (PA required, diabetes only, etc.).

Step 3: Check the PA criteria. If the formulary lists PA required, look for a link to the PA criteria document. This is usually a separate PDF titled "Prior Authorization Criteria" or "Clinical Coverage Policy." Find the section on GLP-1 receptor agonists or anti-obesity medications.

Step 4: Call your state's Medicaid pharmacy helpline. Every state Medicaid program has a pharmacy helpline for providers and patients. The number is on your Medicaid card or the state Medicaid website. Ask: "Does [state name] Medicaid cover Wegovy or semaglutide for weight loss, and if so, what are the PA requirements?"

Step 5: Verify with your provider. Bring the formulary information to your provider. Ask them to submit a PA if coverage exists. If coverage doesn't exist, ask whether you have a diagnosis (prediabetes, metabolic syndrome) that might qualify you for the diabetes-indicated version.

This process takes 10 to 15 minutes and gives you a definitive answer for your state.

When Medicaid denial is actually a coverage error

Not every Medicaid denial is correct. PA denials happen for administrative reasons that can be appealed.

Common correctable denial reasons:

Missing documentation. The PA form asks for BMI, comorbidities, and prior treatment history. If the provider's office submits the form without attaching lab results or visit notes, the claim gets denied. Resubmitting with complete documentation often reverses the denial.

Wrong diagnosis code. If the provider lists E66.9 (obesity, unspecified) without adding a comorbidity code (I10 for hypertension, E78.5 for hyperlipidemia), some state systems auto-deny. Adding the comorbidity code and resubmitting can trigger approval.

Outdated formulary tier. Some state Medicaid programs move medications between tiers mid-year. If the provider's billing system has the old tier information, the claim processes incorrectly. Calling the pharmacy helpline to verify the current tier and resubmitting fixes this.

PA submitted to the wrong entity. Some states use a pharmacy benefit manager (PBM) to handle Medicaid drug claims. The PA has to go to the PBM, not directly to the state Medicaid office. If the provider sends the PA to the wrong address, it sits unprocessed. Verifying the correct submission address and resending resolves this.

Timeframe error. Most state Medicaid programs require PA submission before the prescription is filled. If the patient fills the prescription and then the provider submits the PA retroactively, the claim denies. The provider has to submit the PA first, wait for approval, then the patient fills.

If your PA is denied and you believe you meet the criteria, ask your provider to request a peer-to-peer review. This is a phone call between your provider and the Medicaid medical director to discuss the clinical rationale. Peer-to-peer reviews reverse about 30% to 40% of initial denials (MACPAC, 2025).

You also have the right to file a formal appeal. Every state Medicaid program has an appeals process outlined in the denial letter. Appeals take 30 to 90 days but have a higher success rate than resubmissions (around 50% overturn rate for clinical denials).

The FormBlends Four-Question Medicaid Coverage Decision Tree

We built this decision framework based on patterns across 2,400+ Medicaid-eligible patient consultations between 2024 and 2026.

Question 1: Does your state Medicaid program cover GLP-1s for obesity?

• Yes (you live in one of the 14 coverage states) → Go to Question 2
• No → Go to Question 3

Question 2: Do you meet your state's PA criteria (BMI threshold, comorbidities, prior treatment)?

• Yes → Have your provider submit PA; expect approval in 5 to 14 days; monthly cost $0 to $3
• No → Go to Question 3

Question 3: Do you have type 2 diabetes, prediabetes (A1C ≥5.7%), or metabolic syndrome?

• Yes → Ask your provider to prescribe the diabetes-indicated version (Ozempic or Mounjaro); expect coverage in 48 states with PA; monthly cost $0 to $3
• No → Go to Question 4

Question 4: Can you afford $800+ per month out-of-pocket, or do you want to consider compounded semaglutide?

• I can afford brand-name cash price → Pay cash or use GoodRx; monthly cost $900 to $1,100
• I want a lower-cost option → Consider compounded semaglutide through FormBlends or another provider; monthly cost $179 to $299
• Neither option works for me → Discuss non-GLP-1 weight loss interventions with your provider (behavioral therapy, phentermine, metformin off-label, bariatric surgery referral)

[Diagram suggestion: Flowchart with yes/no branches, color-coded by outcome (green = covered by Medicaid, yellow = out-of-pocket required, red = not a candidate). Each endpoint shows estimated monthly cost.]

This tree doesn't replace a provider consultation, but it maps the decision landscape most Medicaid patients face.

FAQ

Does Medicaid cover Wegovy? Fourteen states cover Wegovy through Medicaid as of April 2026: California, Colorado, Connecticut, Delaware, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, and Washington. All require prior authorization. The remaining 36 states do not cover Wegovy for weight loss.

Does Medicaid cover Ozempic for weight loss? No. Medicaid programs cover Ozempic only when prescribed for type 2 diabetes or prediabetes, not for weight loss alone. If you want a GLP-1 for weight loss and don't have diabetes, you need Wegovy (covered in 14 states) or a compounded alternative.

Does Medicaid cover Zepbound? The same 14 states that cover Wegovy generally cover Zepbound (tirzepatide for obesity), though formulary placement varies. Most states that cover GLP-1s for obesity include both semaglutide and tirzepatide options. Check your state's specific formulary.

Can I use the Novo Nordisk savings card if I have Medicaid? No. Federal law prohibits manufacturer copay assistance for any government-funded insurance program, including Medicaid. Using the savings card while on Medicaid violates program rules and can result in penalties for both the patient and the pharmacy.

What if my state doesn't cover weight loss shots but I have prediabetes? If your A1C is 5.7% or higher, you may qualify for Ozempic or Mounjaro under diabetes coverage rules, even if your state doesn't cover the obesity-indicated versions. Ask your provider to prescribe the diabetes-indicated version and submit a PA with your A1C documentation.

How long does Medicaid prior authorization take for GLP-1s? Standard PA timelines range from 5 to 14 business days in most states. Urgent requests (marked by your provider as medically necessary for immediate start) receive expedited review, typically within 72 hours. If the PA is denied, you can appeal, which adds another 30 to 90 days.

Does Medicaid cover compounded semaglutide? No. Medicaid does not cover compounded medications except in rare cases where no FDA-approved alternative exists. Compounded semaglutide is paid out-of-pocket by the patient, with no insurance involvement.

What's the difference between Medicaid covering Ozempic vs Wegovy? Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for obesity. Medicaid programs in 48 states cover Ozempic for diabetes. Only 14 states cover Wegovy for obesity. The active ingredient (semaglutide) is the same; the indication determines coverage.

Can I appeal a Medicaid denial for Wegovy? Yes. Every state Medicaid program has a formal appeals process. Your denial letter will include instructions. Appeals typically require your provider to submit additional clinical documentation or participate in a peer-to-peer review with the Medicaid medical director. Appeal success rates are around 50% for clinical denials.

Does Medicaid cover Mounjaro? Medicaid programs in 47 states cover Mounjaro (tirzepatide) when prescribed for type 2 diabetes, with prior authorization. Coverage for obesity (Zepbound, the same medication) is limited to the same 14 states that cover Wegovy.

How much does Wegovy cost if Medicaid doesn't cover it? Cash price is $1,200 to $1,400 per month. With a GoodRx or similar discount card, expect $950 to $1,100. Compounded semaglutide alternatives cost $179 to $299 per month through telehealth platforms.

Why doesn't federal Medicaid cover weight loss medications? The Social Security Act (Section 1927) explicitly excludes weight loss drugs from mandatory Medicaid coverage. This provision was written in 1993 to prevent federal spending on diet pills. It hasn't been updated to account for modern obesity medications like GLP-1s, leaving coverage decisions to individual states.

Sources

1. Social Security Act, Section 1927(d)(2). Exclusion of certain drugs. 42 U.S.C. § 1396r-8.
2. West Virginia Department of Health and Human Resources. Medicaid Pharmacy Program Budget Report. 2026.
3. Medicaid and CHIP Payment and Access Commission (MACPAC). Report to Congress on Medicaid and CHIP. March 2025.
4. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Kaiser Family Foundation. Medicaid Beneficiary Out-of-Pocket Spending Patterns. 2024.
6. Compounded GLP-1 Market Analysis. Market Research Report on Compounded Semaglutide and Tirzepatide. 2025.
7. Garber AJ et al. AACE Clinical Practice Guidelines for the Diagnosis and Management of Obesity. Endocrine Practice. 2025.
8. Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b).
9. Novo Nordisk. Wegovy Savings Card Terms and Conditions. 2026.
10. Eli Lilly. Zepbound Savings Card Program Eligibility. 2026.
11. California Department of Health Care Services. Medi-Cal Pharmacy Formulary. 2026.
12. New York State Department of Health. Medicaid Preferred Drug List. 2026.
13. Texas Health and Human Services. Medicaid Vendor Drug Program Formulary. 2026.
14. North Carolina Department of Health and Human Services. Medicaid Clinical Coverage Policy: Anti-Obesity Agents. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.